Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company has submitted a new drug application
for omarigliptin, its investigational once-weekly DPP-4 inhibitor for
the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and
Medical Devices Agency (PMDA).
Language:
English
Contact:
MerckMedia:Pam Eisele267-305-3558orKim Hamilton908-740-1863 / 908-391-0131orInvestors:Justin Holko908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more